SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 24.35% growth in the revenue at Rs. 5724.90 millions for the quarter ended March 2022 as compared to Rs. 4603.80 millions during the year-ago period.Net profit of the cmpany stood at Rs. 277.50 millions for the quarter ended March 2022 a decline of -63.12% from Rs. 752.50 millions  in the same quarter last year.Operating Profit reported a sharp decline to 500.50 millions from 1173.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5724.90 4603.80 24.35 21840.20 19669.80 11.03 21840.20 19669.80 11.03
Other Income 69.30 62.10 11.59 320.40 243.00 31.85 320.40 243.00 31.85
PBIDT 500.50 1173.80 -57.36 2883.20 6161.40 -53.21 2883.20 6161.40 -53.21
Interest 23.40 14.40 62.50 82.90 58.30 42.20 82.90 58.30 42.20
PBDT 477.10 1159.40 -58.85 2661.00 6103.10 -56.40 2661.00 6103.10 -56.40
Depreciation 110.10 99.70 10.43 432.60 389.20 11.15 432.60 389.20 11.15
PBT 367.00 1059.70 -65.37 2228.40 5713.90 -61.00 2228.40 5713.90 -61.00
TAX 89.50 307.20 -70.87 571.80 1268.30 -54.92 571.80 1268.30 -54.92
Deferred Tax 2.10 30.70 -93.16 1.70 -187.20 -100.91 1.70 -187.20 -100.91
PAT 277.50 752.50 -63.12 1656.60 4445.60 -62.74 1656.60 4445.60 -62.74
Equity 587.10 587.10 0.00 587.10 587.10 0.00 587.10 587.10 0.00
PBIDTM(%) 8.74 25.50 -65.71 13.20 31.32 -57.86 13.20 31.32 -57.86

IOL Chem & Pharma Share Price

96.98 -0.90 (-0.92%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×